Literature DB >> 26244529

Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer.

Rosemary D Cress1, Yingjia S Chen, Cyllene R Morris, Megan Petersen, Gary S Leiserowitz.   

Abstract

OBJECTIVE: To identify characteristics associated with long-term survival for patients with epithelial ovarian cancer using the California Cancer Registry.
METHODS: A descriptive analysis of survival of all California residents diagnosed with epithelial ovarian cancer between 1994 and 2001 was conducted using patients identified through the cancer registry with follow-up through 2011. Characteristics of the patients who survived more than 10 years (long-term survivors) were compared with three other cohorts: patients who survived less than 2 years, those who survived at least 2 but no more than 5 years, and those who survived at least 5 but no more than 10 years.
RESULTS: A total of 3,582 out of 11,541 (31%, confidence interval 30.2-31.8%) of the patients survived more than 10 years. Younger age, early stage, low-grade, and nonserous histology were significant predictors of long-term survival, but long-term survivors also included women with high-risk cancer.
CONCLUSION: Long-term survival is not unusual in patients with epithelial ovarian cancer, even in those with high-risk disease. Many of the prognostic factors are well known, but it remains to be determined why some patients with advanced-stage high-grade cancers survive longer than others with the same histology. These findings are important for patient counseling. LEVEL OF EVIDENCE: III.

Entities:  

Mesh:

Year:  2015        PMID: 26244529      PMCID: PMC4545401          DOI: 10.1097/AOG.0000000000000981

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  61 in total

1.  Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients.

Authors:  Christina L Clarke; Lawrence H Kushi; Jessica Chubak; Pamala A Pawloski; Joanna E Bulkley; Mara M Epstein; Andrea N Burnett-Hartman; Bethan Powell; Celeste L Pearce; Heather Spencer Feigelson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-04-09       Impact factor: 4.254

2.  Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies.

Authors:  Maurie Markman
Journal:  Womens Health (Lond)       Date:  2016-07

3.  Long-Term Gynecological Cancer Survivors in Côte d'Or: Health-Related Quality of Life and Living Conditions.

Authors:  Ariane Mamguem Kamga; Agnès Dumas; Florence Joly; Oumar Billa; Julien Simon; Marie-Laure Poillot; Ariane Darut-Jouve; Charles Coutant; Pierre Fumoleau; Patrick Arveux; Tienhan Sandrine Dabakuyo-Yonli
Journal:  Oncologist       Date:  2018-12-21

4.  A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.

Authors:  Kathleen N Moore; Austin Miller; Katherine M Bell-McGuinn; Russell J Schilder; Joan L Walker; Roisin E O'Cearbhaill; Saketh R Guntupalli; Deborah K Armstrong; Andrea R Hagemann; Heidi J Gray; Linda R Duska; Cara A Mathews; Alice Chen; David O'Malley; Sarah Gordon; Paula M Fracasso; Carol Aghajanian
Journal:  Gynecol Oncol       Date:  2019-11-07       Impact factor: 5.482

5.  The expression of asparaginyl endopeptidase promotes growth potential in epithelial ovarian cancer.

Authors:  Qinyi Zhu; Meiling Tang; Xipeng Wang
Journal:  Cancer Biol Ther       Date:  2017-03-03       Impact factor: 4.742

6.  Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.

Authors:  Sherri L Stewart; Rhea Harewood; Melissa Matz; Sun Hee Rim; Susan A Sabatino; Kevin C Ward; Hannah K Weir
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

7.  Long-Term Tumor-Free Survival in a Patient with Stage IV Epithelial Ovarian Cancer Undergoing High-Dose Chemotherapy and Viscum album Extract Treatment: A Case Report.

Authors:  Paul G Werthmann; Robert Kempenich; Gunver S Kienle
Journal:  Perm J       Date:  2018

Review 8.  Can advanced-stage ovarian cancer be cured?

Authors:  Steven Narod
Journal:  Nat Rev Clin Oncol       Date:  2016-01-20       Impact factor: 66.675

9.  Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.

Authors:  Peter G Rose; James J Java; Ritu Salani; Melissa A Geller; Angeles Alvarez Secord; Krishnansu S Tewari; David P Bender; David G Mutch; Michael L Friedlander; Linda Van Le; Michael W Method; Chad A Hamilton; Roger B Lee; Robert M Wenham; Saketh R Guntupalli; Maurie Markman; Franco M Muggia; Deborah K Armstrong; Michael A Bookman; Robert A Burger; Larry J Copeland
Journal:  Obstet Gynecol       Date:  2019-02       Impact factor: 7.661

10.  Deregulated miR-296/S100A4 axis promotes tumor invasion by inducing epithelial-mesenchymal transition in human ovarian cancer.

Authors:  Wang Yan; Jiaqi Chen; Zhaoying Chen; Huimin Chen
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.